Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.

In patients with humoral autoimmune diseases antinuclear antibodies (ANAs) and joint pain are commonly found.[3] In this study, we aimed to provide insight into ANA development during dupilumab treatment in AD patients. Keywords: antinuclear antibodies; atopic dermatitis; autoimmunity; dupilumab; enthesitis; inflammatory arthritis EN antinuclear antibodies atopic dermatitis autoimmunity dupilumab enthesitis inflammatory arthritis 582 585 4 05/10/23 20230501 NES 230501 Key messages Dupilumab-associated muscle and/or joint pain is frequently reported as a side effect in atopic dermatitis patients. During dupilumab treatment only two patients switched from ANA negative to positive after 107 and 109 weeks of dupilumab treatment, respectively, of which one patient was previously diagnosed with rheumatoid arthritis (Table 2). [Extracted from the article]

Copyright of Clinical & Experimental Allergy is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)